Lee Hyun Ju, Kim Dong-Il, Kang Gyeong Hoon, Kwak Cheol, Ku Ja Hyeon, Moon Kyung Chul
Department of Pathology, Seoul National University, College of Medicine, Seoul, Korea.
Urology. 2009 Feb;73(2):394-9. doi: 10.1016/j.urology.2008.08.472. Epub 2008 Oct 11.
To evaluate the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) in clear cell renal cell carcinoma (CCRCC) and to investigate its prognostic significance. ERK1/2 activation had been reported in RCC, but little is known about its prognostic significance.
We immunohistochemically analyzed phosphorylated ERK1/2 (pERK) expression using tissue microarrays in 328 CCRCC specimens. The percentage of tumor cells showing positive staining was evaluated and classified into 4 categories: 0, 0%; 1+, 1%-10%; 2+, 11%-50%; and 3+, > 50%. For statistical analysis, the cases were subdivided into pERK-low (0 and 1+) and pERK-high (2+ and 3+) expression.
Our study showed significantly greater expression of pERK in CCRCC than in non-neoplastic renal parenchyma. pERK-high expression was significantly associated with a low pT category (P = .046). The survival analysis showed a significant association between pERK-high expression and better progression-free survival (P = .014). Furthermore, the prognostic significance of pERK expression was quite different between small CCRCC (size < or = 7 cm) and large CCRCC (size > 7 cm) lesions. In small CCRCC, pERK-high expression correlated significantly with better cancer-specific survival (P = .018) and better progression-free survival (P < .001). However, no correlation was found between pERK expression and survival in large CCRCC.
High expression of pERK in CCRCC was associated with a low pT category and showed a longer progression-free survival, especially in small CCRCC. Although the biologic mechanism of the ERK pathway in CCRCC remains unknown, the results of this study suggest that pERK expression is a positive prognosticator for survival in those with small CCRCC.
评估透明细胞肾细胞癌(CCRCC)中细胞外信号调节激酶1/2(ERK1/2)的磷酸化水平,并探讨其预后意义。已有报道称RCC中存在ERK1/2激活,但对其预后意义了解甚少。
我们使用组织芯片对328例CCRCC标本进行免疫组织化学分析,以检测磷酸化ERK1/2(pERK)的表达。评估显示阳性染色的肿瘤细胞百分比,并将其分为4类:0,0%;1+,1%-10%;2+,11%-50%;3+,>50%。为进行统计分析,将病例分为pERK低表达(0和1+)和pERK高表达(2+和3+)。
我们的研究表明,CCRCC中pERK的表达明显高于非肿瘤性肾实质。pERK高表达与低pT分期显著相关(P = 0.046)。生存分析显示,pERK高表达与更好的无进展生存期显著相关(P = 0.014)。此外,pERK表达的预后意义在小CCRCC(大小≤7 cm)和大CCRCC(大小>7 cm)病变之间有很大差异。在小CCRCC中,pERK高表达与更好的癌症特异性生存期(P = 0.018)和更好的无进展生存期(P < 0.001)显著相关。然而 在大CCRCC中,未发现pERK表达与生存之间存在相关性。
CCRCC中pERK的高表达与低pT分期相关,并显示出更长的无进展生存期,尤其是在小CCRCC中。尽管CCRCC中ERK途径的生物学机制尚不清楚,但本研究结果表明,pERK表达是小CCRCC患者生存的阳性预后指标。